Adamis stock soars as high as 480% amid asset sale, drug study news

Like
1
Favorite

Adamis stock soars as high as 480% amid asset sale, drug study news

seekingalpha2023-08-01

Shares of tiny Adamis Pharmaceuticals (NASDAQ:ADMP) rocketed as high as 480% early Tuesday in the wake of news that it had sold certain assets related to its shuttered pharmacy compounding business ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

yong168
·2023-08-03
opioid and cannabis producers should invest in Adamis Pharmaceuticals: 1. Market Potential: Highlight the growing market demand for solutions to reduce opioid overdose deaths. With Adamis Pharmaceuticals' focus on R&D in this area, investing in the company could present a valuable opportunity to tap into a potentially lucrative market. 2. Positive Social Impact: Emphasize the positive social impact that reducing opioid overdose deaths can have on communities and families affected by addiction. By supporting Adamis Pharmaceuticals, these producers can contribute to saving lives and making a difference in the opioid crisis. 3. Diversification of Portfolio: Investing in a pharmaceutical company like Adamis can diversify their product portfolio and reduce dependency on a single industry. T
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2356927947?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/834714544/image_834714544.jpg","is_english":true,"pubTime":"2023-08-01 23:59","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2356927947","market":"us","top_or_hot":-1,"title":"Adamis stock soars as high as 480% amid asset sale, drug study news","media":"seekingalpha","content":"<div>\n<p>Shares of tiny Adamis Pharmaceuticals (NASDAQ:ADMP) rocketed as high as 480% early Tuesday in the wake of news that it had sold certain assets related to its shuttered pharmacy compounding business ...</p>\n\n<a href=\"https://seekingalpha.com/news/3994306-adamis-stock-soars-amid-asset-sale-drug-study-news\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adamis stock soars as high as 480% amid asset sale, drug study news</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdamis stock soars as high as 480% amid asset sale, drug study news\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-01 23:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3994306-adamis-stock-soars-amid-asset-sale-drug-study-news><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of tiny Adamis Pharmaceuticals (NASDAQ:ADMP) rocketed as high as 480% early Tuesday in the wake of news that it had sold certain assets related to its shuttered pharmacy compounding business ...</p>\n\n<a href=\"https://seekingalpha.com/news/3994306-adamis-stock-soars-amid-asset-sale-drug-study-news\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://seekingalpha.com/news/3994306-adamis-stock-soars-amid-asset-sale-drug-study-news","article_id":"2356927947","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/834714544/image_834714544.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2356927947","pubTimestamp":1690905564,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of tiny Adamis Pharmaceuticals (NASDAQ:ADMP) rocketed as high as 480% early Tuesday in the wake of news that it had sold certain assets related to its shuttered pharmacy compounding business an","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4007":"制药"},"translate_title":"药物研究消息显示，Adamis股票在资产出售中飙升480%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMP":1},"content_text":"Shares of tiny Adamis Pharmaceuticals (NASDAQ:ADMP) rocketed as high as 480% early Tuesday in the wake of news that it had sold certain assets related to its shuttered pharmacy compounding business and was funding testing comparing its drug ZIMHI with Narcan in the treatment of fentanyl overdoses.  Adamis shares were up 280% at $5.50 at around 11:40 a.m. ET after hitting a high of $8.28 earlier in the day. Late Friday, Adamis said in an SEC filing that it had sold the land, building and certain intellectual property assets related to its discontinued compounding business to FarmaKeio Pharmacy Network for around $2M.  Separately on Friday, the biotech company announced that it was funding research at Leiden University Medical Center to assess the effectiveness of its drug ZIMHI versus intranasal naloxone, also known as Narcan, in the treatment of fentanyl-induced respiratory depression. Last week, the company said in a filing that it was planning to offer up to 5.3M units priced at $1.90 per unit. Each unit would consist of one share plus one warrant to buy one share. Adamis merged with DMK Pharmaceuticals in May after conducting a review of strategic alternatives for the company. The drug developer announced the strategic review in October 2022, stating that if it couldn't secure a transaction, it might be forced to declare bankruptcy.  In late September 2022, Adamis shares tumbled after the company said its drug Tempol failed a Phase 2/3 study that evaluated the product in the treatment of early-stage COVID-19.  More on Adamis: Adamis Pharmaceuticals Corporation SEC Filing - Securities Registration Statement (S-1/A) July 28, 2023 Adamis Pharmaceuticals Corporation SEC Filing - Securities Registration Statement (S-1/A) July 26, 2023 Adamis Pharma slips 19% on plans for reverse stock slip","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":204634957660296,"gmtCreate":1690993028334,"gmtModify":1690993183007,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3570966674623757","idStr":"3570966674623757"},"htmlText":"opioid and cannabis producers should invest in Adamis Pharmaceuticals: 1. Market Potential: Highlight the growing market demand for solutions to reduce opioid overdose deaths. With Adamis Pharmaceuticals' focus on R&amp;D in this area, investing in the company could present a valuable opportunity to tap into a potentially lucrative market. 2. Positive Social Impact: Emphasize the positive social impact that reducing opioid overdose deaths can have on communities and families affected by addiction. By supporting Adamis Pharmaceuticals, these producers can contribute to saving lives and making a difference in the opioid crisis. 3. Diversification of Portfolio: Investing in a pharmaceutical company like Adamis can diversify their product portfolio and reduce dependency on a single industry. T","listText":"opioid and cannabis producers should invest in Adamis Pharmaceuticals: 1. Market Potential: Highlight the growing market demand for solutions to reduce opioid overdose deaths. With Adamis Pharmaceuticals' focus on R&amp;D in this area, investing in the company could present a valuable opportunity to tap into a potentially lucrative market. 2. Positive Social Impact: Emphasize the positive social impact that reducing opioid overdose deaths can have on communities and families affected by addiction. By supporting Adamis Pharmaceuticals, these producers can contribute to saving lives and making a difference in the opioid crisis. 3. Diversification of Portfolio: Investing in a pharmaceutical company like Adamis can diversify their product portfolio and reduce dependency on a single industry. T","text":"opioid and cannabis producers should invest in Adamis Pharmaceuticals: 1. Market Potential: Highlight the growing market demand for solutions to reduce opioid overdose deaths. With Adamis Pharmaceuticals' focus on R&D in this area, investing in the company could present a valuable opportunity to tap into a potentially lucrative market. 2. Positive Social Impact: Emphasize the positive social impact that reducing opioid overdose deaths can have on communities and families affected by addiction. By supporting Adamis Pharmaceuticals, these producers can contribute to saving lives and making a difference in the opioid crisis. 3. Diversification of Portfolio: Investing in a pharmaceutical company like Adamis can diversify their product portfolio and reduce dependency on a single industry. T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/204634957660296","repostId":2356927947,"repostType":2,"repost":{"id":"2356927947","pubTimestamp":1690905564,"share":"https://ttm.financial/m/news/2356927947?lang=&edition=fundamental","pubTime":"2023-08-01 23:59","market":"us","language":"en","title":"Adamis stock soars as high as 480% amid asset sale, drug study news","url":"https://stock-news.laohu8.com/highlight/detail?id=2356927947","media":"seekingalpha","summary":"Shares of tiny Adamis Pharmaceuticals (NASDAQ:ADMP) rocketed as high as 480% early Tuesday in the wake of news that it had sold certain assets related to its shuttered pharmacy compounding business an","content":"<html><body><p>Shares of tiny Adamis Pharmaceuticals (<span>NASDAQ:ADMP</span>) rocketed as high as 480% early Tuesday in the wake of news that it had sold certain assets related to its shuttered pharmacy compounding business and was funding testing comparing its drug ZIMHI with<span> Narcan in the treatment of fentanyl overdoses. </span></p> <p>Adamis shares were up 280% at $5.50 at around 11:40 a.m. ET after hitting a high of $8.28 earlier in the day.</p> <p>Late Friday, Adamis said in an SEC filing that it had sold the land, building and certain intellectual property assets related to its discontinued compounding business to FarmaKeio Pharmacy Network for around $2M. </p> <p>Separately on Friday, the biotech company announced that it was funding research at Leiden University Medical Center to assess the effectiveness of its drug ZIMHI versus intranasal naloxone, also known as Narcan, in the treatment of fentanyl-induced respiratory depression.</p> <p>Last week, the company said in a filing that it was planning to offer up to 5.3M units priced at $1.90 per unit. Each unit would consist of one share plus one warrant to buy one share.</p> <p>Adamis merged with DMK Pharmaceuticals in May after conducting a review of strategic alternatives for the company. The drug developer announced the strategic review in October 2022, stating that if it couldn't secure a transaction, it might be forced to declare bankruptcy. </p> <p>In late September 2022, Adamis shares tumbled after the company said its drug Tempol failed a Phase 2/3 study that evaluated the product in the treatment of early-stage COVID-19. </p> <h2>More on Adamis:</h2> <p><a href=\"https://laohu8.com/S/ADMP\">Adamis Pharmaceuticals Corporation</a> SEC Filing - Securities Registration Statement (S-1/A) July 28, 2023</p> <p>Adamis Pharmaceuticals Corporation SEC Filing - Securities Registration Statement (S-1/A) July 26, 2023</p> <p>Adamis Pharma slips 19% on plans for reverse stock slip</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adamis stock soars as high as 480% amid asset sale, drug study news</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdamis stock soars as high as 480% amid asset sale, drug study news\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-01 23:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3994306-adamis-stock-soars-amid-asset-sale-drug-study-news><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of tiny Adamis Pharmaceuticals (NASDAQ:ADMP) rocketed as high as 480% early Tuesday in the wake of news that it had sold certain assets related to its shuttered pharmacy compounding business ...</p>\n\n<a href=\"https://seekingalpha.com/news/3994306-adamis-stock-soars-amid-asset-sale-drug-study-news\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/834714544/image_834714544.jpg","relate_stocks":{"BK4568":"美国抗疫概念","BK4007":"制药"},"source_url":"https://seekingalpha.com/news/3994306-adamis-stock-soars-amid-asset-sale-drug-study-news","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2356927947","content_text":"Shares of tiny Adamis Pharmaceuticals (NASDAQ:ADMP) rocketed as high as 480% early Tuesday in the wake of news that it had sold certain assets related to its shuttered pharmacy compounding business and was funding testing comparing its drug ZIMHI with Narcan in the treatment of fentanyl overdoses.  Adamis shares were up 280% at $5.50 at around 11:40 a.m. ET after hitting a high of $8.28 earlier in the day. Late Friday, Adamis said in an SEC filing that it had sold the land, building and certain intellectual property assets related to its discontinued compounding business to FarmaKeio Pharmacy Network for around $2M.  Separately on Friday, the biotech company announced that it was funding research at Leiden University Medical Center to assess the effectiveness of its drug ZIMHI versus intranasal naloxone, also known as Narcan, in the treatment of fentanyl-induced respiratory depression. Last week, the company said in a filing that it was planning to offer up to 5.3M units priced at $1.90 per unit. Each unit would consist of one share plus one warrant to buy one share. Adamis merged with DMK Pharmaceuticals in May after conducting a review of strategic alternatives for the company. The drug developer announced the strategic review in October 2022, stating that if it couldn't secure a transaction, it might be forced to declare bankruptcy.  In late September 2022, Adamis shares tumbled after the company said its drug Tempol failed a Phase 2/3 study that evaluated the product in the treatment of early-stage COVID-19.  More on Adamis: Adamis Pharmaceuticals Corporation SEC Filing - Securities Registration Statement (S-1/A) July 28, 2023 Adamis Pharmaceuticals Corporation SEC Filing - Securities Registration Statement (S-1/A) July 26, 2023 Adamis Pharma slips 19% on plans for reverse stock slip","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}